

References

1. **Adler A, Stratton I, Neil H, et al. (2000):** Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ* ; 321: 412-419.
2. **Ahmad F, Sattar M, Rathore H, et al. (2012):** Exogenous Hydrogen Sulfide (H₂S) Improves The Endothelial And Renal Excretory Functions In Streptozotocin Induced WKY Diabetic Rats. *IJPSR* ; 3(1): 101-110.
3. **Ahmed N (2005):** Advanced glycation endproducts-role in pathology of diabetic complications. *Diabetes Res Clin Pract* ; 67: 3-21.
4. **Almeida J, Zelmanovitz T, Vaz J, Steemburgo T, et al. (2008):** Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. *J Am Coll Nutr* ; 27: 528-537.
5. **American Diabetes Association (2004):** Nephropathy in Diabetes. *Diabetes Care* ; 27: S79-S83.
6. **Ames J (2008):** Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. *Ann N Y Acad Sci* ; 1126: 20-24.
7. **Ames J, Wynne A, Hofmann A, et al. (1999):** The effect of a model melanoidin mixture on faecal bacterial populations in vitro. *Br J Nutr* ; 82: 489-495.
8. **Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley P (2003):** Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes* ; 52: 2110-2120.
9. **Badri S, Khavidaki S, Pezeshki M, Abdollahi M (2011):** A Review of the Potential Benefits of Pentoxifylline in Diabetic and Non-Diabetic Proteinuria. *J Pharm Pharmaceut Sci* ; 14(1): 128-137.
10. **Bailey C and Turner R (1996):** Metformin. *N Engl J Med* ; 334: 574-579.
11. **Bakris G (2001):** A practical approach to achieving recommended blood pressure goals in diabetic patients. *Arch Intern Med* ; 161: 2661-2667.

12. **Barnett A, Bain S, Bouter P, Karlberg B, et al. (2004):** Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* ; 351: 1952-1961.
13. **Beisswenger P, Makita Z, Curphey T, et al. (1995):** Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. *Diabetes* ; 44: 824-829.
14. **Bierhaus A, Schiekofer S, Schwaninger M, et al. (2001):** Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. *Diabetes* ; 50: 2792-2808.
15. **Bierhaus A, Humpert P, Morcos M, et al. (2005):** Understanding RAGE, the receptor for advanced glycation end products. *J Mol Med* ; 83(11):876-886.
16. **Bohlender J, Fukamizu A, Lippoldt A, Nomura T, et al. (1997):** High human renin hypertension in transgenic rats. *Hypertension* ; 29: 428-434.
17. **Bohlender J, Franke S, Stein G, Wolf G (2005):** Advanced glycation end products and the kidney. *Am J Physiol Renal Physiol* ; 289: F645-659.
18. **Bolton W, Cattran D, Williams M, Adler S, Appel G, et al. (2004):** Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol* ; 24: 32-40.
19. **Border W and Noble N (1994):** Transforming growth factor beta in tissue fibrosis. *N Engl J Med* ; 331: 1286-1292.
20. **Borrelli R and Fogliano V (2005):** Bread crust melanoidins as potential prebiotic ingredients. *Mol Nutr Food Res* ; 49: 673-678
21. **Bouma B, Kroon-Batenburg L, et al. (2003):** Glycation induces formation of amyloid cross-beta structure in albumin. *J Biol Chem* ; 278: 41810-41819.
22. **Brenner B, Lawler E, Mackenzie H (1996):** The hyperfiltration theory: a paradigm shift in nephrology. *Kidney Int* ; 49: 1774-1777.

23. **Brenner B, Cooper M, de Zeeuw D, et al. (2001):** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* ; 345: 861-869.
24. **Brosius F (2008):** New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. *Rev Endocr Metab Disord* ; 9: 245-254.
25. **Brownlee M, Vlassara H, Kooney A, et al. (1986):** Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science* ; 232: 1629-1632.
26. **Brownlee M (2001):** Biochemistry and molecular cell biology of diabetic complications. *Nature* ; 414: 813-820.
27. **Bruno R and Gross J (2000):** Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. *J Diabetes Complications* ; 14: 266-271.
28. **Bucala R and Vlassara H (1995):** Advanced glycosylation end products in diabetic renal and vascular disease. *Am J Kidney Dis* ; 26: 875-888.
29. **Burney B, Kalaitzidis R, Bakris G (2009):** Novel therapies of diabetic nephropathy. *Curr Opin Nephrol Hypertens* ; 18: 107-111.
30. **Burns W, Twigg S, Forbes J, Pete J, Tikellis C, et al. (2006):** Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial to-mesenchymal transition: implications for diabetic renal disease. *J Am Soc Nephrol* ; 17: 2484-2494.
31. **Cai W, He J, Zhu L, Peppia M, Lu C, Uribarri J, Vlassara H (2004):** High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. *Circulation* ; 110: 285-291.
32. **Candido R, Forbes J, Thomas M, Thallas V, Dean R, et al. (2003):** A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. *Circ Res* ; 92: 785-792.
33. **Caramori M, Fioretto P, Mauer M (2003):** Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced

- glomerular lesions. *Diabetes* ; 52: 1036-1040.
34. **Caramori M, Gross J, Pecis M, De Azevedo M (1999):** Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8-year follow up study. *Diabetes Care* ; 22: 1512-1516.
35. **Cardenas C, Bordiu E, Bagazgoitia J, Calle-Pascual A (2004):** Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, populationbased, observational multicenter study. *Diabetes Care* ; 27: 1454-1457.
36. **Celletti F, Waugh J, Amabile P, et al. (2001):** Vascular endothelial growth factor enhances atherosclerotic plaque progression. *Nat Med* ; 7: 425-429.
37. **Cerami C, Founds H, Nicholl I, et al. (1997):** Tobacco smoke is a source of toxic reactive glycation products. *Proc Natl Acad Sci USA* ; 94(25): 13915-20.
38. **Chagnac A, Weinstein T, Herman M, et al. (2003):** The effects of weight loss on renal function in patients with severe obesity. *J Am Soc Nephrol*;14:1480-86.
39. **Chang C, Chang C, Wu Y, et al.(2011):** Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. *J Biomed Sci* ; 18: 47.
40. **Chang S, Caramori M, Moriya R, Mauer M (2008):** Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients. *Diabetes* ; 57: 1707-1711.
41. **Cho S, Roman G, Yeboah F, et al. (2007):** The road to advanced glycation end products: A mechanistic perspective. *Curr Med Chem* ; 14: 1653-71.
42. **Chobanian A, Bakris G, Black H, et al. (2003):** The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* ; 289: 2560-2572.

43. **Chow F, Nikolic-Paterson D, Ozols E, et al. (2006):** Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. *Kidney Int* ; 69: 73-80.
44. **Comper W, Osicka T, Clark M, MacIsaac R, Jerums G (2004):** Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. *Kidney Int*; 65: 1850-1855.
45. **Comper W and Osicka T (2005):** Detection of urinary albumin. *Adv Chronic Kidney Dis* ; 12: 170-176.
46. **Contreras C and Novakofski K (2010):** Dietary Advanced Glycation End Products and Aging : a review. *Nutrients* ; 2: 1247-1265.
47. **Cooper M, Vranes D, Youssef S, Stacker S, et al. (1999):** Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. *Diabetes* ; 48: 2229-2239.
48. **Cooper M, Thallas V, Forbes J, Scalbert E, Sastra S, et al. (2000):** The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. *Diabetologia* ; 43: 660-664.
49. **Cooper M (2001):** Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. *Diabetologia* ; 44(11): 1957- 72.
50. **Danzig V, Mikova B, Kuchynka P, Benakova H, et al. (2010):** Levels of circulating biomarkers at rest and after exercise in coronary artery disease patients. *Physiol Res* ; 59: 385-392.
51. **Davis B, Forbes J, Thomas M, Jerums G, et al. (2004):** Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. *Diabetologia* ; 47: 89-97.
52. **De Mello V, Zelmanovitz T, Perassolo MS, et al. (2006):** Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. *Am J Clin Nutr* ; 83: 1032-1038.

53. **De Vriese A, Tilton R, Elger M, Stephan C, Kriz W, Lameire N (2001):** Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. *J Am Soc Nephrol* ; 12: 993-1000.
54. **Diamanti-Kandarakis E, Alexandraki K, Piperi C, Aessopos A, et al. (2007):** Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. *Metabolism* ; 56: 129-134.
55. **Doi K, Noiri E, Fujita T (2010):** Role of vascular endothelial growth factor in kidney disease. *Curr Vasc Pharmacol* ; 8(1): 122-128.
56. **Dronavalli S, Duka I, Bakris G (2008):** The pathogenesis of diabetic nephropathy. *Nat Clin Pract Endocrinol Metab* ; 4: 444-452.
57. **Duckworth W, Abaira C, Moritz T, et al. (2009):** Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* ; 360: 129-139.
58. **El-Ghoroury E, El-Saeed G, Kamel S, Afify H, Higazy G (2011):** Advanced Glycated End Products And Malondialdehyde In Platelets And Serum In Type 2 Diabetes Mellitus: Correlation With Glycemic Control. *International Journal Of Academic Research* ; 3(6)
59. **Ferrara N (2002):** VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* ; 2: 795-803.
60. **Ficociello L, Perkins B, Roshan B, et al.(2009):**Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes.*Diabetes Care* ;32:889-93.
61. **Figarola J, Scott S, Loera S, Tessler C, Chu P, et al. (2003):** LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.*Diabetologia* ; 46: 1140-1152.
62. **Figarola J, Shanmugam N, Natarajan R, Rahbar S (2007):** Anti inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. *Diabetes* ; 56: 647-655.
63. **Fioretto P, Steffes M, Sutherland D, et al. (1998):** Reversal of lesions of diabetic nephropathy after pancreas transplantation. *N Engl J Med* ; 339: 69-75.

64. **Fioretto P, Caramori M, Mauer M (2007):** The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture. *Diabetologia* ; 51: 1347-1355.
65. **Flyvbjerg A, Dagnaes-Hansen F, De Zeeuw D, et al. (2002):** Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. *Diabetes* ; 51: 3090-3094.
66. **Forbes J, Cooper M, Thallas V, Burns W, et al. (2002):** Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. *Diabetes* ; 51: 3274-3282.
67. **Forbes J, Thallas V, Thomas M, Founds H, et al. (2003):** The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. *FASEB J* ; 17: 1762-1764.
68. **Forbes J, Thomas M, Thorpe S, et al. (2004):** The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. *Kidney Int Suppl* ; 92: S105-S107.
69. **Forbes J, Yee L, Thallas V, et al. (2004):** Advanced glycation end product interventions reduce diabetes accelerated atherosclerosis. *Diabetes* ; 53: 1813-23.
70. **Forbes J, Thorpe S, Thallas-Bonke V, et al. (2005):** Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. *J Am Soc Nephrol* ; 16: 2363-72.
71. **Forsblom C, Groop P, Ekstrand A, Totterman K, et al. (1998):** Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. *Diabetes Care* ; 21: 1932-1938.
72. **Friedman R and Gross J (1991):** Evolution of glomerular filtration rate in proteinuric NIDDM patients. *Diabetes Care* ; 14: 355-359.
73. **Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, et al. (2004):** AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. *Kidney Int* ; 66: 2137-2147.

74. **Fukami K, Yamagishi S, Ueda S, et al. (2007):** Novel therapeutic targets for diabetic nephropathy. *Endocr Metab Immune Disord Drug Targets* ; 7: 83-92.
75. **Fukami K, Yamagishi S, Ueda S, Okuda S (2008):** Role of AGEs in Diabetic Nephropathy. *Current Pharmaceutical Design* ; 14: 946-952.
76. **Futrakul N and Futrakul P (2011):** Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes. *Int J Vasc Med* ; 2011: 971524.
77. **Futrakul N and Futrakul P (2011):** Diabetic Nephropathy: Current Concept of Therapeutic Strategy Toward Self-Sufficiency. *J Nephrol Therapeutic* ; 1: 3
78. **Futrakul N and Futrakul P (2011):** Indices Indicating Early Renal Microvascular Disease in Diabetes. *The Open Biomarkers Journal* ; 4:18- 20
79. **Futrakul N, Kulaputana O, Futrakul P, et al. (2011):** Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuric type 2 diabetic nephropathy. *Ren Fail* ; 33: 312-315.
80. **Gall M, Nielsen F, Smidt U, Parving H (1993):** The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. *Diabetologia* ; 36: 1071-1078.
81. **Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G (2003):** Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl) lysine ELISA. *Diabetes Care* ; 26: 2609-2615.
82. **Genuth S, Sun W, Cleary P, Sell D, Dahms W, et al. (2005):** Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. *Diabetes* ; 54: 3103-3111.
83. **Ghidoni R, Benussi L, Glionna M, Franzoni M, Geroldi D, et al. (2008):** Decreased plasma levels of soluble receptor for advanced glycation end

- products in mild cognitive impairment. *J Neural Trans* ; 115: 1047-1050.
84. **Goh S and Cooper M (2008):** The Role of Advanced Glycation End Products in Progression and Complications of Diabetes. *J Clin Endocrinol Metab* ; 93: 1143-1152.
85. **Goldberg T, Cai W, Peppas M, et al. (2004):** Advanced glycoxidation end products in commonly consumed foods. *J Am Diet Assoc* ; 104: 1287-1291.
86. **Goldin A, Beckman J, Schmidt A, Creager M (2006):** Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation* ; 114: 597-605.
87. **Goon J, Aini A, Musalmah M, Anum M, et al. (2009):** Effect of Tai Chi exercise on DNA damage, antioxidant enzymes, and oxidative stress in middle-age adults. *J Phys Act Health* ; 6: 43-54.
88. **Gordon L, Morrison Y, McGrowder D, Young R, et al. (2008):** Effect of exercise therapy on lipid profile and oxidative stress indicators in patients with type 2 diabetes. *BMC Complement Altern Med* ; 8: 21.
89. **Gross J, De Azevedo M, Silveiro S, et al. (2005):** Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* ; 28: 164-176.
90. **Gu L, Hagiwara S, Fan Q, Tanimoto M, et al. (2006):** Role of receptor for advanced glycation endproducts and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. *Nephrol Dial Transplant* ; 21: 299-313.
91. **Hammes H, Ali S, Uhlmann M, Weiss A, et al. (1995):** Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. *Diabetologia* ; 38: 269-273.
92. **Hammes H, Du X, Edelstein D, Taguchi T, et al. (2003):** Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med* ; 9: 294-299.

93. **Hartog J, De Vries A, Lutgers H, Meerwaldt R, et al. (2005):** Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. *Ann NY Acad Sci* ; 1043: 299-307.
94. **He C, Koschinsky T, Buening C, Vlassara H (2001):** Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. *Mol Med* ; 7: 159-168.
95. **Holman R, Paul S, Bethel M, Matthews D, et al. (2008):** 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* ; 359: 1577-1589.
96. **Hoppmann S, Steinbach J, Pietzsch J (2010):** Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. *Int J Biochem Cell Biol* ; 42: 651-661.
97. **Horiuchi S, Unno Y, Usui H, Shikata K, et al. (2005):** Pathological roles of advanced glycation end product receptors SRA and CD36. *Ann N Y Acad Sci* ; 1043: 671-675.
98. **Hostetter T, Troy J, Brenner B (1981):** Glomerular hemodynamics in experimental diabetes. *Kidney Int* ; 19: 410-415.
99. **Hovind P, Tarnow L, Oestergaard PB, Parving H (2000):** Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. *Kidney Int Suppl* ; 75: S56-61.
100. **Hovind P, Rossing P, Tarnow L, Parving H (2003):** Smoking and progression of diabetic nephropathy in type 1 diabetes. *Diabetes Care* ; 26: 911-916.
101. **Hsu D and Zimmer V (2010):** Canadian Diabetes Association National Nutrition Committee Technical Review: Advanced Glycation End-products in Diabetes Management. *Canadian Journal Of Diabetes* ; 34(2): 136-40.
102. **Huang Q (2011):** Ezrin/Radixin/Moesin Proteins in the Development of Diabetes and its Cardiovascular Complications. *J Diabetes Metab* ; S: 4.

103. **Huebschmann A, Regensteiner J, Vlassara H, et al. (2006):** Diabetes and advanced glycoxidation end products. *Diabetes Care.* ; 29: 1420-1432.
104. **Humpert P, Djuric Z, Kopf S, Rudofsky G, et al. (2007):** Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. *Cardiovasc Diabetol* ; 6: 9.
105. **Incerti J, Zelmanovitz T, Camargo J, Gross J, et al. (2005):** Evaluation of tests for microalbuminuria screening in patients with diabetes. *Nephrol Dial Transplant* ; 20: 2402-2407.
106. **Inzucchi S (2002):** Oral antihyperglycemic therapy for type 2 diabetes: scientific review. *JAMA* ; 287: 360-372.
107. **Isoda K, Young J, Zirlik A, MacFarlane L, et al. (2006):** Metformin inhibits proinflammatory responses and nuclear factor-kappa B in human vascular wall cells. *Arterioscler Thromb Vasc Biol* ; 26: 611-617.
108. **Jakus V and Rietbrock N (2004):** Advanced glycation end-products and the progress of diabetic vascular complications. *Physiol Res* ; 53(2): 131-142.
109. **Jandeleit-Dahm K, Lassila M, Allen T (2005):** Advanced glycation end products in diabetes-associated atherosclerosis and renal disease. *Ann N Y Acad Sci* ; 1043: 759-766.
110. **Jenkins A, Lyons T, Zheng D, et al. (2003):** Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. *Kidney Int* ; 64: 817-828.
111. **Jensen L, Denner L, Schrijvers B, et al. (2006):** Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. *J Endocrinol* ; 188: 493-501.
112. **Jerums G, Allen T, Campbell D, Cooper M, et al. (2001):** Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. *Am J Kidney Dis* ; 37: 890-899.
113. **Kalousova M, Zima T, Tesar V, Stipek S, et al. (2004):** Advanced glycation end products in clinical nephrology. *Kidney Blood Press Res* ; 27(1): 18-28.

114. **Kang M, Park Y, Kim B, Seo S, et al. (2012):** Preventive effects of green tea (Camellia Sinensis var. Assamica) on diabetic nephropathy. *Yonsei Med J* ; 53(1): 138-144.
115. **Kass D, Shapiro E, Kawaguchi M, Capriotti A, et al. (2001):** Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. *Circulation* ; 104: 1464-1470.
116. **Kelly D, Gilbert R, Cox A, et al. (2001):** Aminoguanidine ameliorates overexpression of pro-sclerotic growth factors and collagen deposition in experimental diabetic nephropathy. *J Am Soc Nephrol* ; 12: 2098-2107.
117. **Kikuchi A, Shinpo K, Takeuchi M, et al. (2003):** Glycation – a sweet tempter for neuronal death. *Brain Res Rev.* ; 41: 306-323.
118. **Kisch E and Ayalon D (2003):** Advanced glycosylated end products derived from external sources contribute to diabetic complications. *Pract Diabetes Int.* ; 7: 259-261.
119. **Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, et al. (1997):** Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. *Proc Natl Acad Sci USA* ; 94: 6474-6479.
120. **Krishan P and Chakkarwar V (2011):** Diabetic nephropathy: Aggressive involvement of oxidative stress. *J Pharm Educ Res* ; 2(1): 35-41
121. **Krolewski A, Ng D, Canani L, Warram J (2001):** Genetics of diabetic nephropathy: how far are we from finding susceptibility genes? *Adv Nephrol Necker Hosp* ; 31: 295-315.
122. **Lam K, Cheing I, Jamis E, et al. (1995):** Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. *Diabetologia* ; 38: 604-609.
123. **Landete J (2011):** Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health. *Food Research International* ; 44(5): 1150-1160

124. **Lassila M, Jandeleit-Dahm K, Seah K, et al. (2005):** Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. *J Am Soc Nephrol* ; 16: 363-373.
125. **Lee W, Ou H, Hsu W, Chou M, Tseng J, et al. (2010):** Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. *J Vasc Surg* ; 52(5): 1290-1300.
126. **Leehey D, Singh A, Alavi N, Singh R (2000):** Role of angiotensin II in diabetic nephropathy. *Kidney Int Suppl* ; 77: S93-98.
127. **Leitao C, Canani L, Polson P, et al. (2005):** Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. *Diabetes Care* ; 28: 1724-1729.
128. **Levey A, Coresh J, Balk E, Kausz A, Levin A, et al. (2003):** National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* ; 139: 137-147.
129. **Lewis E, Hunsicker L, Bain R, Rohde R (1993):** The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* ; 329: 1456-1462.
130. **Li F, Drel V, Szabo C, Stevens M, Obrosova I (2005):** Low-dose poly (ADP ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. *Diabetes* ; 54: 1514-1522.
131. **Li Y, Mitsuhashi T, Wojciechowicz D, et al. (1996):** Molecular identity and cellular distribution of advanced glycation end product receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. *Proc Natl Acad Sci USA* ; 93: 11047-11052.
132. **Li Y and Aronow W (2011):** Diabetes Mellitus and Cardiovascular Disease. *J Clinic Experiment Cardiol* ; 2: 114
133. **Lin L, Park S, Lakatta E (2009):** RAGE signaling in inflammation and arterial aging. *Front Biosci* ; 14: 1403-1413.

134. **Lindholm L, Ibsen H, Dahlof B, Devereux R, Beevers G, et al. (2002):** Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet* ; 359: 1004-1010.
135. **Lorenzi M (2007):** The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. *Exp Diabetes Res* ; 2007: 61038.
136. **Lu C, He J, Cai W, Liu H, Zhu L, Vlassara H (2004):** Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. *Proc Natl Acad Sci USA* ; 101: 11767-72.
137. **Lu J, Randell E, HanY, Adeli K, Krahn J, Meng Q (2011):** Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. *Clinical Biochemistry* ; 44: 307-311.
138. **Lukic I, Humpert P, Nawroth P, Bierhaus A (2008):** The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. *Ann N Y Acad Sci* ; 1126: 76-80.
139. **Lutgers H, Graaff R, Links T, Ubink-Veltmaat L, et al. (2006):** Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care* ; 29: 2654-2659.
140. **Lutgers H, Graaff R, De Vries R, et al. (2010):** Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease. *Eur J Clin Invest* ; 40: 812-817.
141. **Maillard L (1912):** Action des acides aminés sur les sucres. Formation des mélanoids par voie méthodique. *C R Acad Sci* ; 154: 66-68.
142. **Makita Z, Radoff S, Rayfield E, et al. (1991):** Advanced glycosylation end products in patients with diabetic nephropathy. *N Engl J Med* ; 325: 836-842.
143. **Mamputu J and Renier G (2004):** Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. *J Leukoc Biol* ; 75: 1062-1069.

144. **Matsui T, Yamagishi S, Nakamura K, Inoue H, Takeuchi M (2007):** Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. *J Int Med Res* ; 35: 107-112.
145. **Matsui T, Yamagishi S, Ueda S, Nakamura K, et al. (2007):** Telmisartan, an angiotensin II type 1 receptor antagonist, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator- activated receptor- γ activation. *J Int Med Res* ; 35: 482-489.
146. **McRobert E, Gallicchio M, Jerums G, Cooper M, Bach L (2003):** The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. *J Biol Chem* ; 278(28): 25783-25789.
147. **Meerwaldt R, Lutgers H, Links T, et al. (2007):** Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care* ; 30: 107-112.
148. **Mezzano S, Aros C, Droguett A, et al. (2004):** NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. *Nephrol Dial Transplant* ; 19: 2505-2512.
149. **Mishra A, Bhatti R, Singh A, et al. (2010):** Ameliorative effect of the cinnamon oil from *Cinnamomum zeylanicum* upon early stage diabetic nephropathy. *Planta Med* ; 76(5): 412-417.
150. **Miura Y, Yamamoto N, Tsunekawa S, et al.(2005):** Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. *Diabetes Care* ; 28: 757-758.
151. **Miyata T, Ueda Y, Horie K, et al. (1998):** Renal catabolism of advanced glycation end products: the fate of pentosidine. *Kidney Int* ; 53: 416-422.
152. **Miyata T, van Ypersele de Strihou C, Ueda Y, et al. (2002):** Angiotensin II receptor antagonists and angiotensin- converting enzyme inhibitors lower in

- vitro the formation of advanced glycation end products: biochemical mechanisms. *J Am Soc Nephrol* ; 13: 2478-2487.
153. **Miyata T, Ishikawa N, van Ypersele de Strihou C (2003):** Carbonyl stress and diabetic complications. *Clin Chem Lab Med* ; 41(9): 1150-1158.
154. **Mizutani K, Ikeda K, Tsuda K, Yamori Y (2002):** Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. *J Hypertens* ; 20: 1607-1614.
155. **Mogensen C, Vestbo E, Poulsen P, et al. (1995):** Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. *Diabetes Care* ; 18: 572-581.
156. **Mogensen C (2003):** Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. *J Intern Med* ; 254: 45-66.
157. **Mollsten A, Dahlquist G, Stattin E, Rudberg S (2001):** Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. *Diabetes Care* ; 24: 805-810.
158. **Murussi M, Baglio P, Gross J, Silveiro S (2002):** Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. *Diabetes Care* ; 25: 1101-1103.
159. **Muthenna P, Akileshwari C, Reddy B (2011):** Ellagic Acid - A New Antiglycating Agent: Inhibition of N-(carboxymethyl)lysine. *Biochemical Journal*
160. **Nakagawa H, Sasahara M, Haneda M, Koya D, et al. (2000):** Immunohistochemical characterization of glomerular PDGF B chain and PDGF beta-receptor expression in diabetic rats. *Diabetes Res Clin Pract* ; 48: 87-98.
161. **Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, et al. (2005):** Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. *Microvasc Res* ; 70: 137-144.

162. **Nakamura S, Makita Z, Ishikawa S, Yasumura K, et al. (1997):** Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. *Diabetes* ; 46: 895-899.
163. **Navaneethan S, Nigwekar S, Sehgal A, et al. (2009):** Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* ; 4: 542-551.
164. **Navarro J, Mora C, Rivero A, et al. (1999):** Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. *Am J Kidney Dis* ; 33 (3): 458-463.
165. **Nosadini R, Velussi M, Brocco E, Bruseghin M, et al. (2000):** Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. *Diabetes* ; 49: 476-484.
166. **Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, et al. (2003):** Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. *Diabetes* ; 52: 2586-2593.
167. **Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, et al. (2002):** Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. *FASEB J* ; 16: 1928-1930.
168. **Okamoto T, Yamagishi S, Inagaki Y, Amano S, et al. (2002):** Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. *Biochem Biophys Res Commun* ; 297: 419-424.
169. **Oldfield M, Bach L, Forbes J, et al. (2001):** Advanced glycation end products cause epithelial- myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). *J Clin Invest* ; 108: 1853-1863.
170. **Oleniuc M, Secara I, Onofriescu M, Hogas S, et al. (2011):** Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Noninvasive Technique – Skin Autofluorescence. *Maedica Journal of Clinical Medicine* ; 6(4)

171. **Pacher P, Liaudet L, Soriano F, Mabley J, Szabo E, Szabo C (2002):** The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. *Diabetes* ; 51: 514-521.
172. **Paffen E and De Maat M (2006):** C-reactive protein in atherosclerosis: A causal factor. *Cardiovasc Res* ; 71: 30-39.
173. **Pan Y, Guo L, Jin H (2008):** Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* ; 88: 660-666.
174. **Park J, Kim H, Chung Y, et al. (1998):** Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. *Diabetes Care* ; 21: 530-34.
175. **Parving H, Lehnert H, Brochner-Mortensen J, et al. (2001):** The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* ; 345: 870-878.
176. **Patel A, MacMahon S, Chalmers J, et al. (2008):** Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* ; 358: 2560-2572.
177. **Pedrini M, Levey A, Lau J, Chalmers T, Wang P (1996):** The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. *Ann Intern Med* ; 124: 627-632.
178. **Peppas M, Brem H, Cai W, Zhang J, et al. (2006):** Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). *Am J Nephrol* ; 26: 430-436.
179. **Perkins B, Ficociello L, Silva K, et al. (2003):** Regression of microalbuminuria in type 1 diabetes. *N Engl J Med* ; 348: 2285-2293.
180. **Pezzolesi M, Poznik G, Mychaleckyj J, et al. (2009):** Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes Mellitus. *Diabetes* ; 58(6): 1403-1410.
181. **Pricci F, Leto G, Amadio L, et al. (2000):** Role of galectin-3 as a receptor for advanced glycosylation end products. *Kidney Int Suppl* ; 77: S31-S39.

- 182. Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, et al. (2000):** The diabetic milieu modulates the advanced glycation end product- receptor complex in the mesangium by inducing or upregulating galectin-3 expression. *Diabetes* ; 49: 1249-1257.
- 183. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, et al. (2001):** Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. *FASEB J* ; 15: 2471-2479.
- 184. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M (2002):** Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. *Eur J Intern Med* ; 13: 428.
- 185. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler J (2000):** Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. *Clin Chim Acta* ; 301: 65-77.
- 186. Ravid M, Neumann L, Lishner M (1995):** Plasma lipids and the progression of nephropathy in diabetes mellitus type-2: effect of ACE inhibitors. *Kidney Int* ; 47: 907-910.
- 187. Ravid M, Brosh D, Ravid-Safran D, Levy Z, et al. (1998):** Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. *Arch Intern Med* ; 158: 998-1004.
- 188. Ravid M, Brosh D, Levi Z, Bar-Dayana Y, Ravid D, Rachmani R (1998):** Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* ; 128: 982-988.
- 189. Remuzzi G, Ruggenenti P, Benigni A (1997):** Understanding the nature of renal disease progression. *Kidney Int* ; 51: 2-15.
- 190. Remuzzi G, Schieppati A, Ruggenenti P (2002):** Clinical practice. Nephropathy in patients with type 2 diabetes. *N Engl J Med* ; 346(15): 1145-51.

191. **Riser B, Denichilo M, Cortes P, et al. (2000):** Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. *J Am Soc Nephrol* ; 11: 25-38.
192. **Ritz E, Ogata H, Orth S (2000):** Smoking: a factor promoting onset and progression of diabetic nephropathy. *Diabetes Metab* ; 26(Suppl 4): 54-63.
193. **Roestenberg P, van Nieuwenhoven F, Wieten L, et al. (2004):** Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. *Diabetes Care* ; 27: 1164-1170.
194. **Rogus J, Poznik G, Pezzolesi M, Smiles A, Dunn J, et al. (2008):** High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. *Diabetes* ; 57: 2519-2526.
195. **Ruggenti P and Remuzzi G (1998):** Nephropathy of type-2 diabetes mellitus. *J Am Soc Nephrol* ; 9: 2157-2169.
196. **Saha S, Lasalle B, Clifton G, et al. (2010):** Modulation of Advanced Glycation End Products by Candesartan in Patients with Diabetic Kidney Disease-A Dose-Response Relationship Study *Am J Ther* ; 17: 553-558.
197. **Saiki A, Nagayama D, Ohhira M, Endoh K, et al. (2005):** Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. *International Journal of Obesity* ; 29: 1115-1120.
198. **Saito A, Pietromonaco S, Loo A, Farquhar M (1994):** Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. *Proc Natl Acad Sci USA* ; 91: 9725-9729.
199. **Saito A, Nagai R, Tanuma A, Hama H, Cho K, Takeda T, et al. (2003):** Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. *J Am Soc Nephrol* ; 14: 1123-1131.

200. **Sarafidis P, Stafylas P, Kanaki A, et al.(2008):** Effects of reninangiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. *Am J Hypertens* ; 21: 922-929.
201. **Sato A, Hayashi K, Naruse M, Saruta T (2003):** Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* ; 41: 64-68.
202. **Savikko J, Taskinen E, Von Willebrand E (2003):** Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. *Transplantation* ; 75: 1147-1153.
203. **Sawicki P, Didjurgeit U, Muhlhauser I, et al. (1994):** Smoking is associated with progression of diabetic nephropathy. *Diabetes Care* ; 17:126-131.
204. **Sawicki P, Muhlhauser I, Bender R, Pethke W, Heinemann L, et al. (1996):** Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. *J Internal Medicine* ; 239: 345-352.
205. **Schlueter C, Hauke S, Flohr A, Rogalla P, Bullerdiek J (2003):** Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? *Biochim Biophys Acta* ; 1630(1): 1-6.
206. **Schrijvers B, De Vriese A, Flyvbjerg A (2004):** From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. *Endocr Rev* ; 25(6): 971-1010.
207. **Schwedler S, Verbeke P, Bakala H, Weiss M, et al. (2001):** N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. *Diabetes Obes Metab* ; 3: 230-239.
208. **Sebekova K, Gazdikova K, Syrova D, et al. (2003):** Effects of ramipril in non-diabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. *J Hum Hypertens* ; 17: 265-270.

209. **Sharma K, Eltayeb B, McGowan T, et al. (1999):** Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. *Am J Kidney Dis* ; 34: 818-823.
210. **Shaw J, Wilmot R, Kilpatrick E (2007):** Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. *Diabet Med* ; 24: 1160-1163.
211. **Sheetz M and King G (2002):** Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *JAMA* ; 288: 2579-2588.
212. **Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000):** Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* ; 23(Suppl 2): B21-29.
213. **Singh D, Winocour P, Farrington K (2011):** Oxidative stress in early diabetic nephropathy: fueling the fire. *Nat Rev Endocrinol* ; 7: 176-184.
214. **Singh R, Alavi N, Singh A, Leehey D (1999):** Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. *Diabetes* ; 48: 2066-2073.
215. **Sourris K and Forbes J (2009):** Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy- are these Receptors Valid Therapeutic Targets. *Current Drug Targets* ; 10(1): 42-50
216. **Stirban A, Negrean M, Stratmann B, Gawlowski T, et al. (2006):** Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. *Diabetes Care* ; 29: 2064-2071.
217. **Stitt A, He C, Vlassara H (1999):** Characterization of the advanced glycation end product receptor complex in human vascular endothelial cells. *Biochem Biophys Res Commun* ; 256(3): 549-556.

218. **Stitt A, Gardiner T, Alderson N, Canning P, et al. (2002):** The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. *Diabetes* ; 51: 2826-2832.
219. **Stratton I, Adler A, Neil H, Matthews D, et al. (2000):** Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* ; 321: 405-412.
220. **Sugimoto H, Hamano Y, Charytan D, Cosgrove D, et al. (2003):** Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. *J Biol Chem* ; 278: 12605-12608.
221. **Suzuki D, Toyoda M, Yamamoto N, et al. (2006):** Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. *Intern Med* ; 45: 435-441.
222. **Talts JF, Andac Z, Göhring W, et al. (1999):** Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. *EMBO J* ; 18: 863-870.
223. **Tam X, Shiu S, Leng L, et al. (2011):** Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. *Clin Sci (Lond)* ; 120(2): 81-89.
224. **Tan A, Forbes J, Cooper M (2007):** AGE, RAGE, and ROS in diabetic nephropathy. *Semin Nephrol* ; 27: 130-143.
225. **Tanimoto M, Gohda T, Kaneko S, Hagiwara S, et al. (2007):** Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KKA(y)/Ta mice. *Metabolism* ; 56: 160-167.
226. **Tanji N, Markowitz G, Fu C, Kislinger T, et al. (2000):** Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. *J Am Soc Nephrol* ; 11: 1656-1666.
227. **Thallas-Bonke V, Lindschau C, Rizkalla B, et al. (2004):** Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced

- glycation end product cross-link breaker ALT-711 via a protein kinase C- α -dependent pathway. *Diabetes* ; 53: 2921-2930.
228. **Thallas-Bonke V, Thorpe S, Coughlan M, et al. (2008):** Inhibition of NADPH oxidase prevents AGE mediated damage in diabetic nephropathy through a protein kinase C- {alpha} dependent pathway. *Diabetes* ; 57:460-469.
229. **The Diabetes Control and Complications Trial (DCCT) Research Group (1993):** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* ; 329: 977-986.
230. **The Diabetes Control and Complications Trial (DCCT) Research Group (1995):** Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. *Kidney Int* ; 47: 1703-1720.
231. **The Epidemiology of Diabetes Interventions and Complications (EDIC) study (2003):** Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA* ; 290: 2159-2167.
232. **The UKPDS Group (1998):** Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study. *Lancet* ; 352: 837-853.
233. **The UKPDS Group (1998):** Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ* ; 317: 703-713.
234. **Thielecke F and Boschmann M (2009):** The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. *Phytochemistry* ; 70: 11-24.

235. **Thomas M, Tsalamandris C, MacIsaac R, et al. (2004):** Low molecular weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. *Kidney Int* ; 66: 1167-1172.
236. **Thomas M, Tikellis C, Burns W, Bialkowski K, et al. (2005):** Interactions between renin angiotensin system and advanced glycation in the kidney. *J Am Soc Nephrol* ; 16: 2976-2984.
237. **Thomas M, Bayones J, Thorpe S (2005):** The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. *Curr. Drug Targets* ; 6(4): 453-474
238. **Thornalley P (2003):** Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. *Arch Biochem Biophys* ; 419: 31-40.
239. **Tikoo K, Meena R, Kabra D, Gaikwad A (2008):** Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. *Br J Pharmacol* ; 153(6): 1225-1231.
240. **Toeller M, Buyken A, Heitkamp G, Bramswig S, et al. (1997):** Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. *Diabetologia* ; 40: 1219-1226.
241. **Tombran-Tink J, Chader C, Johnson L (1991):** PEDF: Pigment epithelium-derived factor with potent neuronal differentiative activity. *Exp Eye Res* ; 53: 411-414.
242. **Tsuchida K, Makita Z, Yamagishi S, Atsumi T, et al. (1999):** Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. *Diabetologia* ; 42: 579-588.
243. **Tsukita S and Yonemura S (1999):** Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. *J Biol Chem* ; 274(49): 34507-34510.
244. **Turgut F and Bolton W (2010):** Potential New Therapeutic Agents for Diabetic Kidney Disease. *American Journal of Kidney Diseases* ; 55(5): 928-40

245. **Twigg S, Cao Z, McLennan S, Burns W, et al. (2002):** Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. *Endocrinology* ; 143: 4907-4915.
246. **Uribarri J, Peppia M, Cai W, Goldberg T, Lu M, He C, Vlassara H (2003):** Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. *J Am Soc Nephrol* ; 14: 728-731.
247. **Uribarri J, Cai W, Sandu O, Peppia M, et al. (2005):** Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. *Ann N Y Acad Sci* ; 1043: 461-466.
248. **Uribarri J and Tuttle K (2006):** Advanced glycation end products and nephrotoxicity of high-protein diets. *Clin J Am Soc Nephrol* ; 1: 1293-1299.
249. **Uribarri J, Cai W, Peppia M, et al. (2007):** Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. *J Gerontol A Biol Sci Med Sci* ; 62: 427-433.
250. **Uribarri J, Stirban A, Sander D, Cai W, et al. (2007):** Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and non-diabetic subjects. *Diabetes Care* ; 30: 2579-2582.
251. **Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, et al. (2010):** Advanced glycation end products in foods and a practical guide to their reduction in the diet. *J Am Diet Assoc* ; 110: 911-916.
252. **Viberti G, Bilous R, Mackintosh D, et al.(1983):** Monitoring glomerular function in diabetic nephropathy. A prospective study. *Am J Med* ; 74:256-264.
253. **Viberti G and Wheeldon N (2002):** Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* ; 106: 672-678.
254. **Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, et al. (2002):** Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. *Proc Natl Acad Sci USA* ; 99: 15596-15601.

255. **Vlassara H and Palace M (2002):** Diabetes and advanced glycation end products. *J Intern Med* ; 251: 87-101.
256. **Wang J, Zhang S, Lu K, Chen Y, Mott R, Sato S, et al. (2005):** Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. *Diabetes* ; 54: 243-250.
257. **Wang J, Zhang S, Mott R, Knapp R, Cao W, Lau K, et al. (2005):** Salutory effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. *Diabetes* ; 55: 1678-1685.
258. **Wendt T, Tanji N, Guo J, Kislinger T, et al. (2003):** RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. *Am J Pathol* ; 162: 1123-1137.
259. **Whittier F, Spinowitz B, Wuerth JP (1999):** Pimagedine safety profile in patients with type 1 diabetes. *J Am Soc Nephrol* ; 10: 184A (Abstract A0941).
260. **Wild S, Roglic G, Green A, et al. (2004):** Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* ; 27: 1047-1053.
261. **Wu C, Chen J, Lu K, Chen C, Lin S, Pauling C, et al. (2010):** Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. *Clin Chim Acta* ; 411: 700-704.
262. **Yamamoto Y, Kato I, Doi T, Yonekura H, et al. (2001):** Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. *J Clin Invest* ; 108: 261-268.
263. **Yamagishi S, Amano S, Inagaki Y, Okamoto T, et al. (2002):** Beraprost sodium, a prostaglandin I₂ analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. *Mol Med* ; 8: 546-550.
264. **Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, et al. (2002):** Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. *J Biol Chem* ; 277: 20309-20315.

265. **Yamagishi S, Inagaki Y, Kikuchi S (2003):** Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. *Drugs Exp Clin Res* ; 29: 147-152.
266. **Yamagishi S, Inagaki Y, Okamoto T, Amano S, et al. (2003):** Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. *Kidney Int* ; 63: 464-473.
267. **Yamagishi S and Takeuchi M (2004):** Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. *Drugs Exp Clin Res* ; 30: 169-175.
268. **Yamagishi S, Abe R, Inagaki Y, Nakamura K, et al. (2004):** Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. *Am J Pathol* ; 165: 1865-1874.
269. **Yamagishi S, Matsui T, Nakamura K, Takeuchi M (2005):** Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. *Int J Tissue React* ; 27: 189-95.
270. **Yamagishi S, Takeuchi M, Inoue H (2005):** Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)- injected rats. *Drugs Exp Clin Res* ; 31: 45-51.
271. **Yamagishi S, Takeuchi M, Matsui T, Nakamura K, et al. (2005):** Angiotensin II augments advanced glycation end product induced pericyte apoptosis through RAGE overexpression. *FEBS Lett* ; 579: 4265-4270.
272. **Yamagishi S, Nakamura K, Matsui T, et al. (2006):** Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular

- hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. *J Biol Chem* ; 281: 20213-20220.
273. **Yamagishi S, Nakamura K, Takenaka K, Matsui T, et al. (2006):** Pleiotropic effects of nifedipine on atherosclerosis. *Curr Pharm Des* ; 12: 1543-1547.
274. **Yamagishi S, Fukami K, Ueda S, Okuda S (2007):** Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. *Curr Drug Targets* ; 8: 952-959.
275. **Yamagishi S, Nakamura K, Matsui T (2007):** Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor- γ (PPAR- γ)-modulating activity for the treatment of cardiometabolic disorders. *Curr Mol Med* ; 7: 463-469.
276. **Yamagishi S, Nakamura K, Matsui T, Inoue H, Takeuchi M (2007):** Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. *Med Hypotheses* ; 69: 666-668.
277. **Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, et al. (2007):** Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. *Microvasc Res* ; 75: 130-134.
278. **Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T (2008):** Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. *Current Pharmaceutical Design* ; 14(5): 487-495.
279. **Yan S, Yan S, Herold K, Ramsamy R, Schmidt A (2006):** Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. *Endocrinol Metab Clin North Am* ; 35(3): 511-524, viii.

280. **Yan SF, Ramasamy R, Schmidt A (2008):** Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. *Nature Clin Pract Endocrinol Metab* ; 4: 285-293.
281. **Yip J, Jones S, Wiseman M, Hill C, Viberti G (1996):** Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow up study. *Diabetes* ; 45: 1729-1733.
282. **Yoneda T, Takeda Y, Usukura M, Oda N, et al. (2007):** Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. *Am J Hypertens* ; 20: 1329-1333.
283. **Yoshida T, Yamagishi S, Nakamura K, Matsui T, et al. (2006):** Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. *Diabetologia* ; 49: 3094-3099.
284. **Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, et al. (2006):** Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. *FEBS Lett* ; 580: 2788-2796.
285. **Yoshida T, Yamagishi S, Nakamura K, et al. (2007):** Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. *Vasc Dis Prevent* ; 4: 213-216.
286. **Yoshikawa T, Miyazaki A, Fujimoto S (2009):** Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. *Med Sci Monit* ; 15: H65-H73.
287. **Younessi P and Yoonessi A (2011):** Advanced Glycation End-Products and Their Receptor-Mediated Roles: Inflammation and Oxidative Stress. *Iran J Med Sci* ; 36(3): 154-166.

288. **Zanatta C, Gerchman F, Burtet L, Nabinger G, et al. (2008):** Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* ; 80: 299-304.
289. **Zelmanovitz T, Gross J, Oliveira J, Paggi A, et al. (1997):** The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. *Diabetes Care* ; 20: 516-519.
290. **Zelmanovitz T, Gerchman F, Balthazar A, et al. (2009):** Diabetic nephropathy; review. *Diabetology & Metabolic Syndrome* ; 1:10.
291. **Zimanyi M, Denton K, Forbes J, Thallas-Bonke V, et al. (2006):** A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced glycation end-products. *Diabetologia* ; 49: 801-810.